PRECIGEN, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
PRECIGEN, INC. (PGEN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 4.96 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-04
- PRECIGEN, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 4.54M shares, a 32.95% increase year-over-year.
- PRECIGEN, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 418.66K shares, a 51.66% decline year-over-year.
- PRECIGEN, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 6.00K shares, a 95.44% decline year-over-year.
- PRECIGEN, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 36.00K shares, a 90.46% decline year-over-year.
- PRECIGEN, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 4.32M shares, a 41.29% decline from fiscal 2024.
- PRECIGEN, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 7.36M shares, a 6.20% decline from fiscal 2023.
- PRECIGEN, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 7.85M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.54M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | 4.96M shares 10-Q · filed 2026-08-04 | 4.96M shares derived: sum of 3 quarters · filed 2026-08-04 | 5.00M shares derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | 418.66K shares 10-Q · filed 2026-05-13 | 424.66K shares derived: sum of 2 quarters · filed 2026-05-13 | 460.66K shares derived: sum of 3 quarters · filed 2026-05-13 | 3.87M shares derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | 6.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | 42.00K shares derived: sum of 2 quarters · filed 2026-03-25 | 3.46M shares derived: sum of 3 quarters · filed 2026-03-25 | 4.32M shares 10-K · filed 2026-03-25 |
| 2025-09-30 | 36.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 3.45M shares derived: sum of 2 quarters · filed 2025-11-13 | 4.32M shares 10-Q · filed 2025-11-13 | 4.45M shares derived: sum of 4 quarters · filed 2026-03-25 |
| 2025-06-30 | 3.41M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 4.28M shares 10-Q · filed 2025-08-12 | 4.41M shares derived: sum of 3 quarters · filed 2026-03-25 | 4.79M shares derived: sum of 4 quarters · filed 2026-03-25 |
| 2025-03-31 | 866.15K shares 10-Q · filed 2025-05-14 | 997.65K shares derived: sum of 2 quarters · filed 2026-03-25 | 1.38M shares derived: sum of 3 quarters · filed 2026-03-25 | 6.99M shares derived: sum of 4 quarters · filed 2026-03-25 |
| 2024-12-31 | 131.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | 509.04K shares derived: sum of 2 quarters · filed 2026-03-25 | 6.12M shares derived: sum of 3 quarters · filed 2026-03-25 | 7.36M shares 10-K · filed 2026-03-25 |
| 2024-09-30 | 377.54K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 5.99M shares derived: sum of 2 quarters · filed 2024-11-14 | 7.23M shares 10-Q · filed 2024-11-14 | 7.37M shares derived: sum of 4 quarters · filed 2026-03-25 |
| 2024-06-30 | 5.62M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 6.85M shares 10-Q · filed 2024-08-14 | 6.99M shares derived: sum of 3 quarters · filed 2026-03-25 | 7.19M shares derived: sum of 4 quarters · filed 2026-03-25 |
| 2024-03-31 | 1.24M shares 10-Q · filed 2024-05-14 | 1.38M shares derived: sum of 2 quarters · filed 2026-03-25 | 1.58M shares derived: sum of 3 quarters · filed 2026-03-25 | |
| 2023-12-31 | 141.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | 340.00K shares derived: sum of 2 quarters · filed 2026-03-25 | 7.85M shares 10-K · filed 2026-03-25 | |
| 2023-09-30 | 198.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 7.71M shares 10-Q · filed 2023-11-09 | ||
| 2023-06-30 | 7.51M shares 10-Q · filed 2023-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |